- Home
- GNFT vs INBX Comparison
GNFT vs INBX Comparison
Compare GNFT & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- INBX
- Stock Information
- Founded
- GNFT 1999
- INBX 2010
- Country
- GNFT France
- INBX United States
- Employees
- GNFT 167
- INBX N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- INBX Health Care
- Exchange
- GNFT Nasdaq
- INBX Nasdaq
- Market Cap
- GNFT 189.6M
- INBX 218.9M
- IPO Year
- GNFT 2019
- INBX 2020
- Fundamental
- Price
- GNFT $3.80
- INBX $13.92
- Analyst Decision
- GNFT Strong Buy
- INBX Hold
- Analyst Count
- GNFT 1
- INBX 1
- Target Price
- GNFT $13.00
- INBX N/A
- AVG Volume (30 Days)
- GNFT 9.8K
- INBX 71.1K
- Earning Date
- GNFT 09-19-2024
- INBX 11-14-2024
- Dividend Yield
- GNFT N/A
- INBX N/A
- EPS Growth
- GNFT N/A
- INBX N/A
- EPS
- GNFT 0.47
- INBX 119.38
- Revenue
- GNFT $86,225,222.00
- INBX $1,568,000.00
- Revenue This Year
- GNFT $155.44
- INBX N/A
- Revenue Next Year
- GNFT N/A
- INBX N/A
- P/E Ratio
- GNFT $7.59
- INBX $0.12
- Revenue Growth
- GNFT 175.45
- INBX 19.24
- 52 Week Low
- GNFT $3.31
- INBX $10.80
- 52 Week High
- GNFT $6.42
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- GNFT 29.24
- INBX 38.33
- Support Level
- GNFT $3.63
- INBX $14.53
- Resistance Level
- GNFT $3.88
- INBX $15.24
- Average True Range (ATR)
- GNFT 0.10
- INBX 0.72
- MACD
- GNFT 0.02
- INBX -0.10
- Stochastic Oscillator
- GNFT 15.30
- INBX 19.16
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.